Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →

Supply of Defibrinated Rabbit Blood

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Silver Spring, MD, 20910, USA

Set-Aside

NONE

Documents

This scope was carved out of PANDHA-26-P-0000_046638.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

PANDHA-26-P-0000 046638 Defibrinated Rabbit Blood

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency (dha)
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Supplies defibrinated rabbit blood for prime contractors on Defense Health Agency (DHA) projects. Collects rabbit blood, performs defibrination to meet specifications, and bottles into 50ml units. Generates lot numbers and product data sheets for every unit. Requires biological processing equipment and laboratory-grade bottling. Delivers 48 units of defibrinated rabbit blood per period of performance.

Similar Contracts

Same NAICS industry code

NAICS: 325414
New
DIBBS
JAPANESE ENCEPHALIT
Solicitation # SPE2DP-26-R-0001
The Defense Logistics Agency Troop Support is soliciting Japanese Encephalitis Virus Vaccine, Purified, Inactivated, Single-Dose Prefilled Syringes under solicitation SPE2DP-26-R-0001, with a sole source justification under FAR 6.302-1 due to the unique nature of the product and regulatory requirements. The acquisition will follow Part 12 procedures for commercial items, resulting in a firm-fixed-price, indefinite delivery, indefinite quantity contract with an 18-month base term. The minimum order is 277,760 units, with an estimated and maximum quantity of 277,760 and 394,240 units respectively. Vaccines must be FDA-approved prior to the solicitation’s closing date and must comply with MPID Number 5 dated July 23, 2024. All deliveries are FOB destination to DLA Distribution Susquehanna in New Cumberland, Pennsylvania, with a 120-day production lead time following issuance of each DD1155 delivery order. Inspection and acceptance occur at the delivery point, and the contractor is responsible for certification of conformity with all specifications including FDA regulations and labeling requirements. All packaging, marking, and labeling must adhere to strict government standards including MIL-STD-2073-1 for preservation, MIL-STD-129 for shipping labels, and MIL-STD-130 for item identification. Units must be marked with the NSN, CAGE code, part number, contract number, preservation method and date, and transaction control number, with commercial preservation denoted as “COMM’L” and military as “M” followed by the method and date. Intermediate and exterior containers require bar codes compliant with DoD logistics standards, and hazardous materials necessitate a Shipper’s Declaration for Dangerous Goods and Safety Data Sheets. Shelf life must include at least 12 months remaining at time of delivery for Type I items, with expiration and manufacture dates clearly marked. Each shipment must include a destination label addressed to DODAAC SV3100, and all documentation must be in English using durable, legible markings. The contract requires electronic submission via the DIBBS portal and prohibits paper solicitations. Contractors must maintain inspection records for three years post-delivery and comply with all applicable federal regulations including the Federal Food, Drug, and Cosmetic Act and 49 CFR for hazardous materials. No socioeconomic set-asides apply,
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

3 days ago

DEADLINE

in 28 days
View Details
NAICS: 325414
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.
Mrpbs Minneapolis Mn

POSTED

8 days ago

DEADLINE

in about 1 month
View Details
NAICS: 325414
DIBBS
MEDICAL PHARMACY EMERGENCY NON NSN ORDER
Solicitation # SPE2DP-26-R-0002
Solicitation SPE2DP-26-R-0002 is a federal request for a firm-fixed price, indefinite-delivery, indefinite-quantity contract to establish a source of supply for the Influenza Virus Vaccine, Southern Hemisphere 2027 Formula. The contract, issued by the Medical Supply Chain Pharmacy FSA for the Department of Defense, covers a twelve month term for quadrivalent or trivalent vaccines suitable for individuals aged six months and older. The required product consists of 0.5 ML doses provided in packages of ten syringes. All quantities must be delivered to the Defense Distribution Center in Susquehanna, Pennsylvania, by March 31, 2027, with delivery appointments coordinated through DLA Distribution Susquehanna. Proposals must be submitted exclusively via the DLA Internet Bid Board System by October 14, 2026. Evaluation is based on price and the ability to meet all solicitation terms, including the provision of FDA approval for manufacturers or a manufacturer's Letter of Commitment for dealers. The contractor is responsible for ensuring products comply with USP requirements and the Drug Supply Chain Security Act. Strict packaging and marking standards apply, specifically Medical Marking Standard No. 1D, with rigorous cold chain requirements for refrigerated items (2 to 8 degrees Celsius) and frozen items (-25 to -10 degrees Celsius), including the use of DLA-compatible temperature monitors. Invoicing and payment will be processed electronically through the Wide Area Workflow system.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

11 days ago

DEADLINE

in 5 days
View Details

More opportunities from Department Of Defense → Defense Health Agency (dha)

Same awarding agency

NAICS: 541715
Federal
DHA Enterprise-Wide Commercial Solutions Opening (CSO)
Solicitation # HT003826SC005
The Defense Health Agency (DHA) has established the Enterprise-Wide Commercial Solutions Opening (CSO), solicitation number HT003826SC005, to identify and acquire commercial products, services, and non-developmental items. Active from August 7, 2026, through August 6, 2027, this initiative seeks commercially available capabilities that can be deployed immediately or modified to meet DHA requirements across its Medical Digital Solutions, Medical Services, and Medical Products portfolios. The government will utilize a variety of award vehicles, including firm-fixed-price FAR-based contracts and Other Transaction (OT) agreements for research, prototyping, and experimental purposes under authorities such as 10 U.S.C. 3458, 3201, 4021, 4022, and 4023. The procurement process is driven by the issuance of specific Areas of Interest (AoI), which define problem statements, objectives, and submission criteria. Submissions undergo a streamlined, multi-phase evaluation process: Phase I involves a pitch or white paper evaluated on a Go/No-Go basis for strategic alignment and feasibility; Phase II may include an optional oral presentation or demonstration to assess technical viability; and Phase III requires a full commercial proposal evaluated on technical merit, cost reasonableness, and past performance. This CSO is administered by the DHACA Defense Healthcare Management Systems Contracting Division and is designed to prioritize cost-effective, commercially viable solutions to enhance healthcare readiness and patient safety.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 561910
Federal
DHA - Offsite Sterile Processing Support Services
Solicitation # HT9427-27-RFI-0001
The Defense Health Agency (DHA) is issuing a Request for Information (RFI) to identify qualified contractors capable of providing offsite Sterile Processing (SP) support for various Military Treatment Facilities (MTFs) across eight DHA networks. This initiative is part of a Business Case Analysis to improve service resilience and workload stability, ensuring that surgical capabilities are not halted by onsite equipment failures. The scope of work involves the transportation of surgical instruments between MTFs and contractor-owned offsite facilities, where the contractor will provide the necessary personnel, equipment, and facilities to perform decontamination, assembly, sterilization, inventory verification, and quality control. The equipment to be processed includes specialized items such as minimally invasive surgical cases, Da Vinci accessories, and power equipment, with an estimated volume of approximately 2,000 trays monthly per participating MTF. This RFI is strictly for market research and planning purposes and does not constitute a formal solicitation or an obligation to award a contract. The DHA is seeking capability statements from healthcare companies and hospitals that detail their experience with similar projects over the last five years and their proposed implementation strategy. Responses must be submitted in PDF format to the designated Contract Specialist by 11:00 AM EDT on October 30, 2026, and are limited to 10 pages using a 12-point font. The government has not yet determined if a small business set-aside is appropriate and will use the information gathered from these responses to make that decision.
Packaging and Labeling Services

POSTED

10 days ago

DEADLINE

in 21 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS